A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
R$59,84
arrow_upward
+0,74%(+0,44) 1D
16 ຕ.ລ., 10 ໂມງ 56 ນາທີ 22 ວິນາທີ GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1LN34...
Open
R$59,28
High
R$59,84
Low
R$59,28
Mkt. cap
31,28 ຕື້
Avg. vol.
446,00
Volume
17,00
52-wk high
R$131,80
52-wk low
R$50,25
Shares outstanding
133,81 ລ້ານ
No. of employees
2 ພັນ
Open
R$59,28
High
R$59,84
Low
R$59,28
Mkt. cap
31,28 ຕື້
Avg. vol.
446,00
Volume
17,00
52-wk high
R$131,80
52-wk low
R$50,25
Shares outstanding
133,81 ລ້ານ
No. of employees
2 ພັນ
News stories
From web sources and news partners
The Business Journals
·
4 ຊົ່ວໂມງກ່ອນ
Alnylam founder's new biotech lands $200M in upsized IPO
ChartMill
·
6 ຊົ່ວໂມງກ່ອນ
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum
ad-hoc-news.de
·
23 ຊົ່ວໂມງກ່ອນ
Citigroup cuts target to USD 320 for Alnylam Pharmaceuticals stock
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals Inc Bdr